Independent Medical Education


Daiichi Sankyo supports a variety of independent accredited continuing education (CE) activities. The information on this page is intended to provide self-service to educational topics of interest and activities are free to the learner.

Daiichi Sankyo adheres to the commercial support standards established by the Accreditation Council for Continuing Medical Education (ACCME®). The company also complies with the principles established by the Office of Inspector General (OIG) Compliance Guidance to Pharmaceutical Manufacturers and Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Medical Professionals Independent Medical Education is independently supported by Daiichi Sankyo without any influence over the education. Responsibility and control over content, faculty, and educational material belong solely to the providers/accreditors of these activities.


Therapeutic Areas

Breast Cancer

How I Am Managing Patients With Advanced Breast Cancer During the COVID-19 Pandemic
Activity Enduring from 25-Sept-2020 through 25-Sept-2021
Provided by Clinical Care Options, LLC

How I Manage Interstitial Lung Disease Associated With Trastuzumab Deruxtecan in My Patients With HER2-Positive MBC
Activity Enduring from 10-Sept-2020 through 10-Sept-2021
Provided by Clinical Care Options, LLC

Key Questions and Emerging Research in the Management of HER2-Positive Breast Cancer
Activity Enduring from 1-Sept-2020 through 1-Sept-2021
Provided by Research to Practice

Gastric Cancer

Adding Trastuzumab Deruxtecan to the Treatment Armamentarium for Advanced Gastric Cancers
Activity Enduring from 15-Feb-2021 through 15-Feb-2022
Provided by Clinical Care Options, LLC

Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents
Activity Enduring from 8-Jul-2020 through 7-Jul-2021
Provided by Medical Learning Institute & PeerView Institute

Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies
Activity Enduring from 8-Feb-2021 through 7-Feb-2022
Provided by Medical Learning Institute & PeerView Institute


T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL
Activity Enduring from 21-Dec-2020 through 21-Dec-2021
Provided by Physicians’ Education Resources, LLC

Lung Cancer

Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
Activity Enduring from 26-Jan-2021 through 26-Jan-2022
Provided by Clinical Care Options, LLC

Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care
Activity Enduring from 30-Nov-2020 through 29-Nov-2021
Provided by Medical Learning Institute & PeerView Institute & GO2 Foundation for Lung Cancer

Pan Tumor

Recent Developments in Testing for and Targeting HER2, HER3, and TROP2 in Patients With Advanced Breast, GI, and Other Solid Cancers
Activity Enduring from 23-Jul-2020 through 23-Jul-2021
Provided by Clinical Care Options, LLC

Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types
Activity Enduring from 16-Jun-2020 through 16-Jun-2021
Provided by Physicians’ Education Resource, LLC

Tenosynovial Giant Cell Tumor

The Case for Challenging Conventional Care in Tenosynovial Giant Cell Tumor: Insights on Integrating Targeted Therapy Into Multimodal Management
Activity Enduring from 7-Dec-2020 through 6-Dec-2021
Provided by Medical Learning Institute & PeerView Institute